Berberine Inhibits FOXM1 Dependent Transcriptional Regulation of POLE2 and Interferes With the Survival of Lung Adenocarcinoma

Lulu Ni1†, Ping Sun2†, Xiaochun Fan3†, Zhongjie Li1, Hongli Ren4* and Jiangan Li3*

1Department of Basic Medicine, Jiangnan University, Wuxi, China, 2Department of Pathology, The Affiliated Wuxi NO. 2 People’s Hospital of Nanjing Medical University, Wuxi, China, 3Department of Emergency, The Affiliated Wuxi NO. 2 People’s Hospital of Nanjing Medical University, Wuxi, China, 4Institute of Science, Technology and Humanities, Shanghai University of Traditional Chinese Medicine, Shanghai, China

Background: Berberine is one of the most interesting and promising natural anticancer drugs. POLE2 is involved in many cellular functions such as DNA replication and is highly expressed in a variety of cancers. However, the specific molecular mechanism of berberine interfering with POLE2 expression in lung adenocarcinoma (LUAD) is still unknown to a great extent.

Method: The KEGG database (Release 91.0) and Gene Ontology (GO) category database were used for functional annotation of differentially expressed genes after berberine treatment. Reproducibility assessment using TCGA dataset. The biological functions of berberine in LUAD were investigated by a series of in vitro and in vivo experiments: MTT, colony formation, mouse xenograft and plasmid transfection. The molecular mechanisms of berberine were demonstrated by plasmid transfection, quantitative RT-PCR and Western blotting.

Result: The elevated expression of FOXM1 and the high enrichment of DNA replication pathway were confirmed in LUAD by microarray and TCGA analysis, and were positively correlated with poor prognosis. Functionally, berberine inhibited the proliferation and survival of LUAD cell lines in vitro and in vivo. Mechanistically, berberine treatment downregulated the expression of FOXM1 which closely related to survival, survival related genes in Cell cycle and DNA replication pathway, and significantly downregulated the expression of survival related POLE2. Interestingly, we found that the transcription factor FOXM1 could act as a bridge between berberine and POLE2.

Conclusion: Berberine significantly inhibited LUAD progression via the FOXM1/POLE2, and FOXM1/POLE2 may act as a clinical prognostic factor and a therapeutic target for LUAD. Berberine may be used as a promising therapeutic candidate for LUAD patients.

Keywords: berberine, FOXM1, POLE2, DNA replication, lung adenocarcinoma, survival

Abbreviations: Akt, Protein kinase B; Bcl-2, B-cell lymphoma-2; COX-2, Cyclooxygenase 2; ERK, extracellular regulated protein kinases; FOXM1, Forkhead Box M1; GO, Gene Ontology; LUAD, lung adenocarcinoma; miR-19a, microRNA-19a; MAPK, mitogen-activated protein kinase; NF-κB, nuclear factor-kappa B; NSCLC, Non small cell lung cancer; PRIM1, DNA Primase Subunit 1; POLE2, DNA Polymerase Epsilon 2; TCGA, The Cancer Genome Atlas; TF, Transcription factors
INTRODUCTION

Lung cancer is the malignant tumor with the highest incidence and mortality in the world, and 85% of cases are NSCLC (Torre et al., 2015). Lung adenocarcinoma is the most common subtype of NSCLC, and the five-year overall survival rate is less than 18% (Miller et al., 2019). The initiation of DNA replication is the basic process of cell proliferation, and malignant proliferation is the basic feature of lung cancer cells. It is well known that the occurrence of lung adenocarcinoma is the result of imbalance of tumor suppressor genes or oncogenes, which will lead to uncontrolled proliferation of lung adenocarcinoma cells. In clinical, many mature chemotherapeutic drugs were designed to directly or indirectly inhibit DNA synthesis. Targeted DNA therapy was usually effective for the proliferation and survival of lung adenocarcinoma cells, such as cisplatin and carboplatin. They cross-linked purine bases in DNA, prevented DNA replication and repair of lung adenocarcinoma cells and promoted cell death. However, the side effects of these targeted drugs such as gastrointestinal, nephrotoxicity, ototoxicity and infection were very obvious. Therefore, it is very important and urgent to find high-efficiency and low toxicity anti lung adenocarcinoma drugs.

Plant medicine is a rich source of new pharmacological active agents against diseases. Berberine is a low toxic natural plant alkaloid with broad spectrum of biological and pharmacological activities, including anti diabetes (Wang et al., 2019), antidiarrheal (Joshi et al., 2011), anti-cancer (Liu et al., 2019) and antibacterial (Peng et al., 2015). At present, berberine has been evaluated in many clinical trials. Berberine has low toxicity to healthy cells and high cytotoxicity to cancer cells, which makes its research in anticancer become the most promising. Since the first study on the cytotoxicity in cancer cells of berberine in 1986 (Wang et al., 1986), its anticancer properties have been proved in many cancer cell studies (Kettmann et al., 2004; Yu et al., 2007; Pazhang et al., 2011; Zheng et al., 2014; Och et al., 2019), which makes berberine one of the most interesting and promising natural anticancer drugs.

Although many studies had shown that berberine against lung adenocarcinoma mainly focused on different cell signaling pathways, including Sin3A/TOP2B (Chen et al., 2020), Bcl-2/Bax (Li et al., 2018), mTOR (Kumar et al., 2020) and NF-kB/COX-2, Akt/ERK (Liu et al., 2016), miR-19a/TF/MAPK (Chen et al., 2019), etc. It was not clear whether berberine could exert anticancer effect by interfering with DNA replication, the basic process of lung adenocarcinoma cell proliferation. In this study, we provided evidence that berberine inhibited DNA replication levels in lung adenocarcinoma cells and Lewis tumor xenograft mice. Berberine inhibited the proliferation of lung adenocarcinoma cells by interfering with the expression of POLE2 involved in DNA replication meditated by transcription factor FOXM1. Our study analyzed the mechanism of berberine inhibiting the proliferation of lung adenocarcinoma by using gene chip technology and TCGA, and correlated the changes of genome and transcriptome with cancer cell proliferation, DNA replication and overall survival.

MATERIALS AND METHODS

Experiment Reagents

Berberine were purchased from Shanghai Tongtian Biotechnology Co., Ltd. (shanghai, China). Berberine were dissolved in DMSO and stored at ~20°C. RPMI 1640 and Dulbecco’s modified eagle medium (DMEM) for culture were purchased from Gibco (Grand Island, NY, United States); fetal bovine serum (FBS) was from HyClone (South Logan, United States) and trypsin was from Gibco (Grand Island, NY, United States). Thioureas [3-(45-Dimethylthiazol-2-yl)-2,5-diphenyl-2H-tetrazolium Bromide; Methylthiazolylidiophenyl-tetrazolium bromide (MTT)] were purchased from Sigma (St. Louis, MO, United States). Propidium iodide (PI) and FITC-Annexin V were both purchased from BD Biosciences (San Jose, CA). RNA extraction kit, PrimeScript RT MasterMix kit, and SYBR Premix Ex Taq kit were provided by Takara (Dalian, China). Antibodies against POLE2 was obtained from Santa Cruz (CA, United States). Antibodies against FOXM1 and actin as well as secondary antibodies were purchased from Cell Signaling Technology (Danvers, MA, United States).

Microarray Data Analysis

A549 cells were treated with 120μM berberine for 24 h. Total RNA of berberine treatment and non-berberine treatment were extracted using the Trizol reagent (Invitrogen, Life Technologies) and reversely transcribed to complementary DNA (cDNA) using the Quantscript RT kit (Tiangen Biotech). Hybridization was performed using the Illumina Human-12Tv4 Expression BeadChip system (Illumina, San Diego, CA), which contains 47,231 probes per array product. Slides were scanned by GeneChip® Scanner 3,000 (Cat#00-00212, Affymetrix, Santa Clara, CA, US) and Command Console Software 4.0 (Affymetrix, Santa Clara, CA, US) with default settings. Raw data were normalized by MAS 5.0 algorithm. Statistical significance of differential expression of probe sets between groups were detected by student t test. Probe set with p-value ≤ 0.05 and absolute fold change ≥ 1.5 were considered as differential expressed. One gene keeps only one most statistical significant differential expressed probe set.

Functional Characterization of DEGs

The KEGG database (Release 91.0) and Gene Ontology (GO) category database were used for functional annotation of differentially expressed genes. Enrichment analysis of GO categories was performed by R clusterProfiler (v 3.14.3) package, and enrichment analysis of pathways was tested upon hypergeometric distribution by R “phyper” function. Those GO categories a FDR < 0.05 were considered as significant enriched. While pathways with a p-value < 0.05 were regarded as enriched. Only those GO categories or pathways contains ≥ 5 DEGs were kept for further analysis.

Gene Set Enrichment Analysis

Genes were ranked by log2 (Foldchange). Annotated gene set “c2.cp.kegg.v7.1.symbols.gmt” was selected as the reference gene
set downloaded from the Molecular Signatures Database (MSigDB), and p adjust < FDR and absolute NES >= 1 was considered significant. R package “clusterProfiler” were used to do this analysis. Then we plot the Cell Cycle and DNA replication gene sets in the enrichment score.

**Protein–Protein Interaction**

The interactions between the protein products of DEGs were collected from Pathway Commons database (http://www.pathwaycommons.org/). Pathway Commons provides directed protein–protein interactions. Two criteria were used: Number of protein–protein interactions (PPIs) and largest connected component. 1,000 randomized networks were created. P-value were calculated by compared the observed value with values of randomized networks.

**Reproducibility Assessment Using TCGA Dataset**

The gene expression profiles data of 526 LUAD patients and 59 adjacent cancer samples and clinical characteristics of matched patients were obtained from the Cancer Genome Atlas (TCGA) data portal (Liu et al., 2018). LUAD sequencing data were downloaded. Differential expression of genes between patients and adjacent were detected by “edgeR” (v 3.28.1) package, with a threshold of a FDR $\leq$ 0.05. Then functional enrichment analysis were performed on these DEGs as described above. The clinical data of 522 patients were used for Cox regression analysis.

**Cell Culture and Plasmid Transfection**

Human NSCLC cell lines, A549, H1299, and H1975 cells were purchased from Shanghai Cell Bank of the Chinese Academy of Sciences. A549 cells were cultured with DMEM medium and H1299 and H1975 cells were grown in RPMI 1640 medium. Both DMEM medium and RPMI 1640 medium were supplemented with 10% fetal bovine serum, penicillin (100 U/ml) and streptomycin sulfate (100 $\mu$g/ml). Cells were maintained at 37°C in a humidified 5% CO2 atmosphere. The empty plasmid EX-NEG-M02 (Genecopoeia) and human FOXM1 overexpression plasmid (Genecopoeia) were transfected into A549, H1299, and H1975 cells using Lipofectamine 3,000 reagent (Invitrogen #2024201, MA, United States), according to the manufacturer’s instructions. After that, the A549, H1299, and H1975 cells transfected with the plasmid were used in subsequent experiments.

**MTT Colorimetric Analysis for Determining Inhibition of Cell Proliferation**

To assess the effect of berberine on the survival and proliferation of NSCLC cells, MTT analysis was adopted. A549, H1299 and H1975 cells in the logarithmic phase were seeded in a 96-well plate, at a density of 3,000 cells/well and maintained at 37°C in a humidified 5% CO2 atmosphere for 16 h. Then the berberine at a density of 0, 30, 60, 90, 120, 150, 180, 210, 240, 270 $\mu$M were added, respectively. The total volume was 200 $\mu$L. Every concentration was set as well with four parallel wells in each group and kept at 37°C in a humidified 5% CO2 atmosphere for 24, 48 and 72 h, respectively. When the time was due, 20 $\mu$L of MTT reagent (Sigma) was added to each well in the 96-well plate. Then the plate was kept at 37°C for 4 h. After removing the supernatants, 150 $\mu$L of DMSO was supplemented into each well and then the plate was maintained at 37°C for 15 min. Absorbance (A) was determined with the microplate reader at 570 nm. The cell inhibition was calculated as follows:

$$\text{Inhibition rate} (\%) = \left(\frac{A_{\text{of negative control group}} - A_{\text{of test group}}}{A_{\text{of negative control group}}}\times 100\right)$$

**Determination of Sphere Formation Efficiency**

To clarify the effect of berberine on the tumorigenesis ability of NSCLC cells, plate clone assay was applied. A549, H1975 and H1299 cells (2000 for each type) in the logarithmic phase were seeded in a 6-well plate for 16 h. Then berberine at a density of 0, 5, 10 and 20 $\mu$M were added to NSCLC cells, respectively. The cells were maintained at 37°C in a humidified 5% CO2 atmosphere. Ten days later, the colonies were stained with crystal violet and photographs of the stained colonies were taken by the digital camera and dissecting microscope.

**Determination of the Effects on Transplanted Tumor in C57BL/6 Mice**

C57BL/6 mice aged at 6–8 weeks and weighed at 18–22 g were purchased from SLAC Shanghai and fed in a standard feeding atmosphere at Jiangnan University. LLC cells (3 × 106) were suspended in the medium at 150 $\mu$L and then subcutaneously injected into the right axilla of C57BL/6 mice. After LLC cells were injected, berberine groups were given an intraperitoneal injection of berberine (100, 200 and 400 mg/Kg) continually for 4 weeks. The blank control group was administered intraperitoneally injected with PBS. The volume of the tumor was measured every 3 days with a vernier caliper. The formula for volume was as follows: $V=(\pi/8) \times a \times b^2$. “a” represents the maximum diameter of the tumor, while “b” reflects the shorter diameter vertical to “a”. The C57BL/6 mice with the tumor over 2000 mm3 was put to death by CO2 suffocation.

**HE Staining of Mouse Tumor Were Observed**

The tumors of mice were taken and soaked in 4% paraformaldehyde solution. The 4% paraformaldehyde solution was changed every day. One week later, the fixed specimens were routinely dehydrated with alcohol gradient, transparent xylene, embedded with paraffin, and sectioned 5 m thick. The tumor sections were stained with HE and were observed under microscope.

**Immunohistochemistry Analysis**

To demonstrate the expression of FOXM, immunohistochemistry was used to detect. The tumor sections of mice in each group were observed...
incubated with FOXM1 (Cell Signaling Technology, MA, United States) and detected, respectively, with the secondary antibodies (Cell Signaling Technology, MA, United States).

**Quantitative RT-PCR**

Total RNA from A549, H1299 and H1975 cells was extracted using Trizol reagent after the treatment of 0, 30, 60, 120 μM berberine for 24 h. 1 μg of total RNA was transcribed to cDNA using the PrimeScript™ RT Master Mix kit (TaKaRa, China) according to the protocols. Quantitative RT-PCR was performed in a reaction volume of 20 μL cDNA on ABI system (Applied Biosystems, Life Technologies), and carried out with the following parameters: 95°C for 30 s, amplifications were carried out with 40 cycles at a melting temperature of 95°C for 5 s and an annealing temperature of 60°C for 30 s, followed by melt curve analysis. The relative expression was calculated using the 2−ΔΔCt. The following four genes were selected for analysis: RRM1, RRM2, POLE2, and LIG1. An 18 S was used as an internal reference gene to normalize the expression of all genes. Primers for all genes were listed as follows: 18 S forward: GTAAACCGTGAACCCCATTT; 18 S reverse: CCATCCATCGGTAGTACCG. POLD1 forward: ATCCGAAACTTCGACCTTCC; POLD1 reverse: ACGGCA TTGACGCTGTAG. DNA2 forward: AGAGCTGTCCTG AGTGAACAC; DNA2 reverse: GAAAACCTCATGGAGAA CCG. POLE2 forward: TTTTGCAGAAGTCTTCACAGATG; POLE2 reverse: TTCCTCTTCATTCGACTCAG; RFC5 reverse: GCAGAAGGTTGGTTTGAAGA. RFC5 forward: GACGAACGGCAAACTCCTGT. MCM2 forward: ATCTAC GCAAAGGAGGAGGT; MCM2 reverse: GATATGGGGAGATG CTTGCTGT. MCM4 forward: CTGTCCATTTGCAAAAGGCTG; MCM4 reverse: GAGACTCAATGGGGATGCTG. MCM6 forward: CTGTGATGAGGCCTCAACCT; MCM6 reverse: GAC ATCAGGTTTCTCCACAC. RFC3 forward: CCCTGAGACAGA TAGGGGAG; RFC3 reverse: TCAAGGAGCTTTTGGAGAG. FEN1 forward: GATATGTCTTCAAGCCCTTGAC; FEN1 reverse: TCA AAAACAGACACAGC. POLA2 forward: CTCTCCAAGTGC TACTCCC; POLA2 reverse: ATACTCCCTGTCTGAAGCC. PRIM1 forward: CTAAAACCTTTATACCGGGAGG; PRIM1 reverse: GTTATTTTTAATCTACCTCCACCC. PRIM2 forward: GGTGTTAACTTGTGGGAGGC; PRIM2 reverse: TTCCCTTCT GGGTGCTTGA; FOXM1 forward: ATAGCTGGATGAGGACC ACT; FOXM1 reverse: TCCAATGTAAGGCGGTG.

**Western Blotting for Determining Protein**

A549, H1299 and H1975 cells in the logarithmic phase were seeded in 10 cm culture dishes. When cells occupied 80% of the dish, berberine were used for intervention. berberine at a density of 0, 30, 60, 120 μM were added to A549, H1299 and H1975 cells, respectively. 24 h later, 100 μL RIPA was added to the dishes and cells were fully soaked. After centrifugation for 30 min, supernatants were collected for protein measurement. After being washed with 95°C water for 10 min, the proteins were separated with gel and transferred to a membrane. The membranes were incubated overnight at 4°C with the primary antibodies and then further incubated with secondary antibodies and finally visualized.

**Statistical Analysis**

The relationship between Cell cycle or DNA repair pathway related gene expression and overall survival of TCGA—LUAD patients was analyzed using COX regression. p < 0.05 was considered to have significant statistical significance. all these analysis were conducted using R (v. 3.6.0).

**RESULTS**

**Altered Pathway and Genes After Berberine Treatment**

To screen for potential differentially expressed genes (DEGs), we analyzed the transcriptome of three berberine treated and three untreated A549 cells by microarray. The results showed that nearly 76% of DEGs were down-regulated after berberine treatment, compared with control group (Figure 1A). KEGG pathway and Gene Ontology enrichment of these DEGs after berberine treatment were highly enriched in Cell cycle and DNA replication pathway, and tended to be down-regulated (Figures 1B,C). And we reproduced this finding by Gene Set enrichment analysis (GSEA). GSEA revealed that Cell Cycle and DNA replication pathway were the most enriched (Supplementary Figure S1), and A549 cells treated with berberine showed a declining phenotype of Cell Cycle and DNA replication (Figure 1D). Therefore, we guess the DEGs of Cell Cycle and DNA replication might have crucial roles after berberine treatment. We name these DEGs as CC-DEGs and visualized in a scatter plot with the x-axis as log2 (FoldChange) and y-axis as log10 (Pvalue). The CC-DEGs were colored in green. Some of the CC-DEGs shows high differential expression at the down-regulated region with high-log10 (p-value) and absolute log2 (FoldChange) (Figure 1E). Next, we investigate the tendency for the protein products of CC-DEGs to physically interact with other DEGs. Enrichment for protein-protein interactions (PPIs) between CC-DEGs and other DEGs was observed relative to random expectation (Figure 1F, empirical p < 10−5). We then evaluated whether Cell cycle and DNA replication genes densely interact with other DEGs by calculating the size of the largest connected component between CC genes and other DEGs. Enrichment for protein-protein interactions (PPIs) between CC-DEGs and other DEGs was observed relative to random expectation (Figure 1F, empirical p < 10−5). This results further indicate that the important role of CC-DEGs after berberine treatment.

**Berberine Down Regulated Survival Related Genes in Cell Cycle and DNA Replication Pathway**

To further explore the effect of berberine on Cell cycle and DNA replication pathway, we analyzed the data in 59 adjacent normal tissues and 526 Lung adenocarcinoma (LUAD) tumor tissues from The Cancer Genome Atlas (TCGA). 8,876 genes were up-regulated and 4,937 genes were down-regulated when tumor compared with the adjacent normal tissues by the cutoff of a FDR < 0.05. Functional enrichment of these DEGs showed that Cell cycle pathway was statistically enriched (Supplementary Figures
S2A,B) and up-regulated in tumor. In TCGA, the differential genes were mainly enriched in purine metabolism and Cell cycle, and tended to be up-regulated. But, almost all of the differentially expressed genes in DNA replication were up-regulated (Supplementary Figure S2A). From this result, we learned that Cell cycle, DNA replication pathways were significantly altered and up-regulated in tumor samples. Considering whether berberine could down-regulate these Cell cycle and DNA repair related genes. We compared the DEGs from comparison of adjacent of TCGA-LUAD date and 646 DEGs from berberine treated lung adenocarcinoma cells, 480 genes were common differential expressed, among which 321 were common down and 56 common up regulated (Figure 2A). Functional enrichment of these 377 coexist DEGs with the same up-down direction showed that Cell cycle and DNA replication pathways were the most significant enriched (Figure 2B). And the heatmap plot of the differential status of these Cell Cycle and DNA replication related genes in the berberine treated lung adenocarcinoma cells showed that except for three genes, the rest genes were down-regulated (Figure 2C). Besides, the DNA replication related genes which tended to have lower p-value were more significant altered than the Cell Cycle genes. Among these DNA replication related DEGs, MCM2, MCM3, MCM4 and DNA2 had lower p-value and POLE2 and PRIM1 had larger fold change (Figures 2D,E). All these results suggested that berberine might interfere with tumor progression mainly by down regulating gene expression of Cell cycle and DNA replication.

Next, we wondered whether berberine would selectively act on survival related genes, rather than randomly altered DEGs in Cell cycle and DNA replication screened from the clinical samples. Firstly, we classify these Cell cycle and DNA replication related genes into survival or non-survival related by Cox ph analysis. Genes with a p-value < 0.05 were regarded as survival related. We found that survival related DEGs tend to differentially expressed after berberine treatment (Figure 2F), especially reflected in DNA replication pathway. Nearly 90% survival related DEGs in DNA replication were also differentially expressed after berberine treatment, While those DEGs not alterd by berberine tended to be survival unrelated (Figure 2F), and berberine also had more significant effect on differential survival related genes in DNA replication pathway (Figure 2D). In addition, those survival genes...
related DEGs in Cell cycle or DNA replication pathway, although there was no significant difference after berberine treatment, a large proportion tended to be down regulated (Supplementary Figures S2, S3).

**Berberine Down Regulated the Expression of FOXM1 Related to Survival**

To further investigate the effect of berberine on survival related genes in DNA replication pathway, then we analyzed the upstream regulation of DNA replication related differential genes after berberine treatment. The results showed that except FOSL1, the numbers of target genes regulated by other transcription factors or their cofactors were almost the same (Figure 3A). Next, we carried out the survival analysis of the above transcription factors and their cofactors in TCGA-LUAD data, and only FOXM1 met the p value < 0.05, showed high expression and low survival (Figure 3B). In addition, we analyzed the differential expression of FOXM1 in TCGA-LUAD. The results showed that FOXM1 was highly expressed in clinical cancer tissues (Figure 3C), berberine treatment decreased significantly (Figure 3D). And the functional enrichment results of downstream regulatory genes of FOXM1 showed that Cell cycle and DNA replication pathway were significantly enriched, and mainly inclined to up-regulated genes (Supplementary Figure S4). After that, we verified it on non-small cell lung cancer cells. The results showed that the mRNA and protein lever expression of FOXM1 were down regulated in...
A549, H1299 and H1975 cells after berberine treatment, and it was the most significant in H1975 cells (Figures 3E–G).

**Berberine Inhibited the Survival of NSCLC Cells**

Since berberine could inhibit the expression of FOXM1 related to survival, whether berberine could really inhibit the survival of NSCLC cells, then we carried out the cellular verification. A549, H1299 and H1975 cells were treated with berberine (0, 30, 60, 90, 120, 150, 180, 210, 240, 270 μM) for 24, 48 and 72 h, respectively. The results showed that when the concentration was 120 μM, the number of NSCLC cells was reduced and the morphology shrunk significantly (Figures 4A,B), and the inhibitory effect was enhanced with the increase of concentration (Figure 4B). Berberine is quite sensitive to H1975 cells, even at very low concentration, the inhibition rate was very high (Figure 4B). Then, we further studied the effect of berberine on the tumorigenesis of NSCLC cells by plate cloning. The results showed that after treatment of berberine (0, 5, 10, 20 μM), the
clone number of NSCLC cells decreased with the increase of concentration (Figures 4C,D). 10 and 20 μM could completely inhibit the formation of NSCLC cells (p < 0.001, p < 0.001, p < 0.001) (Figure 4D). At high magnification, we found that the clone size of control group was very large, while that of berberine group was significantly reduced (Figure 4C). These results suggest that berberine could inhibit the survival of NSCLC cells.

**Berberine Inhibited the Survival of Lung Cancer Xenografts and Down Regulated the Expression of FOXM1 in vivo**

In lung cancer cells, we have just confirmed that berberine can inhibit the survival of NSCLC cells. Then we tested the effect of berberine on the survival of lung cancer xenografts in more complex animals. We injected LLC cells into the right armpit of c57bl/6 mice. Berberine with 100, 200 and 400 mg/kg concentration were used for gastric administration. After 4 weeks, we found that high, medium and low concentrations of berberine could significantly inhibit the growth of lung cancer transplantation (p < 0.01, p < 0.001, p < 0.001) (Figures 5A,B), and the medium concentration of berberine had the most significant inhibition effect on the growth of lung cancer transplantation (Figures 5A,B). In addition, berberine with medium and low concentration significantly prolonged the survival time of lung cancer transplanted mice (Figure 5C). Then we performed HE staining and immunohistochemistry analysis of the tumor. The results of microscope showed that the tumor necrosis area of berberine group was significantly increased compared with the blank control group (Figure 5E). And berberine could significantly reduce the expression of FOXM1 in tumor (p < 0.05) (Figure 5F).

**Berberine Interfered the Expression of Survival Related Genes POLE2 in DNA Replication Mediated by FOXM1**

To verify that berberine inhibited the survival related genes in DNA replication pathway through FOXM1. We further analyzed the network relationship between FOXM1 and DNA replication related differential genes after berberine treatment, and found that not all the differentially expressed target genes were survival related (Figure 6A). Then, we used univariable Cox proportional hazards regression analysis to analyze the survival of DNA replication related genes in TCGA data, and found out the survival related genes in DNA replication (Figure 6B). We verified the common genes of the above two analyses by PCR in A549 cells and found that berberine down regulated the expression of MCM4, POLA2, POLE2 and PRIM1 in A549 cells (Figure 6C). At the same time, we found that MCM4, POLA2, POLE2 and PRIM1 were involved in G1/S transition of mitotic Cell cycle and DNA replication, while berberine could significantly down regulate their expression, especially on POLE2 and PRIM1 (Figure 6D). And berberine could significantly down regulate POLE2 and PRIM1 in A549 cells, H1299 cells and H1975 cells (Figure 6E). In addition, we found that berberine did not reduce the expression of POLE2 when FOXM1 was overexpressed, but could significantly reduce the expression of PRIM1 (Figure 6F). Moreover, we collected the peak information...
of FOXM1 binding sites in the pole2 genome region from the UCSC Genome Browser and found that there was a FOXM1 binding peak in the pole2 promoter region (Supplementary Figure S5). This suggested that FOXM1 bound to the POLE2 promoter region to regulate POLE2 expression. These results indicated that berberine affected the survival of NSCLC cells by inhibiting the expression of POLE2 through FOXM1.

**DISCUSSION**

Gene chip technology and Cancer Genome Atlas (TCGA) have been proved to be reliable diagnostic and prognostic tools for cancer patients (Sato et al., 2013; Team, 2017; Wang et al., 2017). This independent data stored in a public database enables researchers to explore the potential mechanisms of diagnosis and treatment. In this study, in order to reveal the molecular mechanism of berberine intervention in the survival of lung adenocarcinoma cells, we analyzed the differential expression of genes in A549 cells treated with berberine and in the lung adenocarcinoma cohort created by TCGA, then determined the importance of DNA replication pathway, and deeply analyzed the relationship between DNA replication of lung adenocarcinoma cells and berberine intervention in the survival of lung adenocarcinoma patients. The results showed that the differentially expressed genes were mainly enriched in the Cell cycle and DNA replication pathway after berberine treatment, and were significantly down regulated. In previous studies, we used flow cytometry to detect the cell cycle, berberine could effectively induce G1/S phase arrest of NSCLC cells. We used the samples of lung adenocarcinoma tumor and adjacent tissues in cancer genome map and lung adenocarcinoma cells before and after berberine treatment for common differential expressed gene analysis. The results showed that there were 321 ± 56 common
differentially expressed genes, mainly related to Cell cycle and DNA replication pathway. After berberine treatment, these differentially expressed genes were mainly downregulated, and most of these differentially expressed genes were survival related genes. Berberine had a more significant effect on differential survival related genes in DNA replication pathway than that in Cell cycle pathway. These results suggested that berberine could significantly affect the survival related genes in lung adenocarcinoma, especially in the DNA replication pathway.

It is well known that transcription factors (TF) play a major role in tumorigenesis and tumor progression by widely promoting or blocking the transcription of their targets. Identifying TF with malignant characteristics can provide a comprehensive view for explaining tumor biology. Forkhead/wing helix domain transcription factor FOXM1, as an oncoprotein, affected the occurrence and development of cancer through trans activation of related oncogenes (Halasi and Gartel, 2013; Kalathil et al., 2020). Its expression had been proved to be increased in various cancers (Halasi and Gartel, 2013; Nandi et al., 2018). It was worth noting that FOXM1 had been reported as the primary gene expression biomarker with poor prognosis in Pan-cancer analysis, which includes >18,000 tumors from 39 different malignancies (Gentles et al., 2015). The high expression of FoxM1 was closely related to the reduction of patient survival (Li et al., 2017; Barger et al., 2019). People were interested in the therapeutic target of FoxM1 in cancer (Tabatabaei Dakhili et al., 2019; Ziegler et al., 2019). FoxM1 had recently been identified as a key transcriptional regulator of related oncogenes in lung adenocarcinoma. In our study, the expression of FoxM1 was down regulated in lung

![Diagram showing the effect of berberine on differentially expressed genes](image-url)
adenocarcinoma cells after berberine treatment, most significantly in H1975 cells. At the same time, berberine could also inhibit the growth and clone formation of lung adenocarcinoma cells. In vivo, we also found that berberine inhibited the survival of lung adenocarcinoma xenografts and significantly down regulated the expression of FOXM1. In conclusion, berberine could significantly inhibit the survival of lung adenocarcinoma through FOXM1.

FOXM1 played an important role in DNA replication. FOXM1 was recently reported to induce DNA replication pressure in vitro, and FOXM1 expression was observed to be associated with the expression of DNA replication pressure biomarkers in several cancer types (Li et al., 2020). In order to evaluate the role of FOXM1 in DNA replication of lung adenocarcinoma cells, we further analyzed the transcriptional regulation of related differential genes in DNA replication pathway. We found that the number of target genes regulated by transcription factors or their cofactors was almost the same except FOSL1. However, in TCGA data, we analyzed the survival of the above transcription factors and their cofactors, and only FOXM1 met $p < 0.05$, showing high expression and low survival rate. We further analyzed the network relationship between FOXM1 and related differentially expressed genes in DNA replication pathway after berberine treatment, and also found that most differentially expressed target genes were related to survival. We used univariate Cox proportional hazards regression analysis to find survival related genes in DNA replication in TCGA data. Then, the common differential expressed gene in the above two analyses was verified by PCR. It was found that berberine could down regulated the expression of POLE2 and PRIM1.

It was worth noting that our study also found FOXM1 was closely related to POLE2. POLE2 was involved in cell functions, such as DNA replication, repair and Cell cycle control (Burgers, 1998), as well as array based proliferation characteristics (Rosenwald et al., 2003). On the other hand, POLE2 had been previously reported to be highly expressed in breast cancer, colorectal cancer, cervical cancer and bladder cancer (Zhou et al., 2008; Liu et al., 2014; Chubb et al., 2016). We overexpressed FOXM1 and found that berberine could not reduce the expression of POLE2, but could significantly reduce the expression of PRIM1, indicating that FOXM1 mediated the expression of POLE2. In conclusion, berberine intervened the survival of lung adenocarcinoma cells by inhibiting the expression of POLE2 mediated by FOXM1.

In conclusion, we found that berberine could significantly inhibit the DNA replication pathway in lung adenocarcinoma cells through gene chip technology of lung adenocarcinoma A549 cells and TCGA data analysis. We found that berberine could significantly inhibit the proliferation of lung adenocarcinoma cells in vitro and in vivo. In addition, we demonstrated that the therapeutic target of berberine was to inhibit the expression of FOXM1 and POLE2 mediated by FOXM1, so as to intervene the survival of lung adenocarcinoma (Overview of this study). This is the first study on the mechanism of berberine in the treatment of lung adenocarcinoma by regulating FOXM1 and POLE2 mediated by FOXM1. It is also the first time to confirm the significance and relationship of FOXM1 and its target gene POLE2 in lung adenocarcinoma.
DATA AVAILABILITY STATEMENT

The original contributions presented in the study are included in the article/Supplementary Material, further inquiries can be directed to the corresponding authors.

ETHICS STATEMENT

The animal study was reviewed and approved by the All of the procedures were reviewed and approved by the Animal Ethics Committee of Jiangnan University before and during the experiment.

AUTHOR CONTRIBUTIONS

LN and JL conceived and designed the study; LN, PS, and XF performed the experiments and collected the data; ZL and HR contributed to analyzing the data; NL wrote the manuscript; JL and HR made manuscript revisions. All authors have read and approved the manuscript.

REFERENCES

Barger, C. J., Bronick, C., Chee, L., and Karpf, A. R. (2019). Pan-Cancer Analyses Reveal Genomic Features of FOXM1 Overexpression in Cancer. *Cancers (Basel)* 11, 1. doi:10.3390/cancers11010025

Burgers, P. M. (1998). Eukaryotic DNA Polymerases in DNA Replication and DNA Repair. *Chromosoma* 107, 218–227. doi:10.1007/s004120050300

Chen, J., Huang, X., Tao, C., Wang, L., Chen, Z., Li, X., et al. (2020). Berberine Chloride Suppresses Non-Small Cell Lung Cancer by Deregulating Sin3A/TOP2B Pathway *In Vitro* and *In Vivo*. *Cancer Chemother. Pharmacol.* 86, 151–161. doi:10.1007/s00280-020-04050-y

Chen, Q. Q., Shi, J. M., Ding, Z., Xia, Q., Zheng, T. S., Ren, Y. B., et al. (2019). Berberine Induces Apoptosis in Non-small-cell Lung Cancer Cells by Upregulating miR-19a Targeting Tissue Factor. *Cancer Manag. Res.* 11, 9005–9015. doi:10.2147/CMAP.S207677

Chubb, D., Broderick, P., Dobbins, S. E., Frampton, M., Kinnersley, B., Penegar, S., et al. (2020). Berberine. *Front. Pharmacol.* 11, 151. doi:10.3389/fphar.2020.00253

Li, Z., Yu, D. S., Doetsch, P. W., and Werner, E. (2020). Replication Stress and FOXM1 Drive Radiation Induced Genomic Instability and Cell Transformation. *PLoS One* 15, e0235998. doi:10.1371/journal.pone.0235998

Liu, D., Meng, X., Wu, D., Qiu, Z., and Luo, H. (2019). A Natural Isoquinoline Alkaloid with Antitumor Activity: Studies of the Biological Activities of Berberine. *Front. Pharmacol.* 10, 9. doi:10.3389/fphar.2019.00909

Liu, D., Zhang, X. X., Xi, B. X., Wan, D. Y., Li, L., Zhou, J., et al. (2014). Sine Oculis Homeobox 1 Promotes DNA Replication and Cell Proliferation in Cervical Cancer. *Int. J. Oncol.* 45, 1232–1240. doi:10.3892/ijo.2014.2510

Liu, J., Lichtenberg, T., Hoddley, K. A., Poisson, I. M., Lazar, A. J., Cherniak, A. D., et al. (2018). An Integrated TCGA Pan-Cancer Clinical Data Resource to Drive High-Quality Survival Outcome Analytics. *Cell* 173, 400–e11. doi:10.1016/j.cell.2018.02.052

Lu, J. F., Fu, L., Tang, Z., Zhang, C., Qin, L., Wang, J., et al. (2016). Melatonin Inhibits AP-2δ/ERK2 and Akt/ERK and Activates caspase/Cyto C Signaling to Enhance the Antitumor Activity of Berberine in Lung Cancer Cells. *Onco Targets Ther.* 9, 2985–3001. doi:10.18632/oncotarget.6407

Miller, K. D., Nogueira, L., Mariotto, A. B., Rowland, J. H., Yabroff, K. R., Alfano, C. M., et al. (2019). Cancer Treatment and Survivorship Statistics, 2019. *CA Cancer J. Clin.* 69, 363–385. doi:10.3322/caac.21565

Nandi, D., Cheema, P. S., Jaiswal, N., and Nag, A. (2018). FOXM1: Repurposing an Oncogene as a Biomarker. *Semin. Cancer Biol.* 52, 74–84. doi:10.1016/j.semcancer.2017.08.009

Och, A., Zalewski, D., Komsta, L., Kołodziej, P., Kocki, J., and Bogucka-Kocka, A. (2019). Cytotoxic and Proapoptotic Activity of Sanguinarine, Berberine, and Extracts of Chileanum Majus L. And Berberis Thunbergii DC. toward Hematopoietic Cancer Cell Lines. *Toxins (Basel)* 11, 1. doi:10.3390/toxins11090485

Pazhang, Y., Ahmadian, S., Mahmoudian, M., and Shahzad, M. (2011). Berberine-induced Apoptosis via Decreasing the Survivin Protein in K562 Cell Line. *Med. Oncol.* 28, 1577–1583. doi:10.3109/13880209.2010.500295

Rosenwald, A., Wright, G., Wiestner, A., Chan, W. C., Connors, J. M., Campo, E., et al. (2002). The Prognostic Landscape of Genes and Infiltrating Immune Cells Modulating Cell Cyclins and Inflammation Independent of mTOR Pathway. *Semin. Cancer Biol.* 12, 245–254. doi:10.1158/1053-734X.MCT-12-0712

Rosenwald, A., Wright, G., Wiestner, A., Chan, W. C., Connors, J. M., Campo, E., et al. (2002). The Prognostic Landscape of Genes and Infiltrating Immune Cells Modulating Cell Cyclins and Inflammation Independent of mTOR Pathway. *Semin. Cancer Biol.* 12, 245–254. doi:10.1158/1053-734X.MCT-12-0712

Semenov, N. A., Morozov, A. Y., Botvinkin, A. G., Kryuchkov, S. G., Sirota, V. I., et al. (2015). Antioxidant and Antitumoral Activity of Berberine. *Pharmazie* 70, 584–591. doi:10.1024/0001-695X-7005.584

Ni et al. Berberine Interferes With LUAD Survival

SUPPLEMENTARY MATERIAL

The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fphar.2021.775514/full#supplementary-material
Tabatabaei Dakhili, S. A., Pérez, D. J., Gopal, K., Tabatabaei Dakhili, S. Y., Ussher, J. K., and Velázquez-Martínez, C. A. (2019). A Structure-Activity Relationship Study of Forkhead Domain Inhibitors (FDI): The Importance of Halogen Binding Interactions. *Bioorg. Chem.* 93, 103269. doi:10.1016/j.bioorg.2019.103269

Team, A. S. (2017). Shared Gene Expression Alterations in Nasal and Bronchial Epithelium for Lung Cancer Detection. *J. Natl. Cancer Inst.* 109, 1. doi:10.1093/jnci/djw327

Torre, L. A., Bray, F., Siegel, R. L., Ferlay, J., Lortet-Tieulent, J., and Jemal, A. (2015). Global Cancer Statistics, 2012. *CA Cancer J. Clin.* 65, 87–108. doi:10.3322/caac.21262

Wang, J. T., Peng, J. G., Zhang, J. Q., Wang, Z. X., Zhang, Y., Zhou, X. R., et al. (2019). Novel Berberine-Based Derivatives with Potent Hypoglycemic Activity. *Bioorg. Med. Chem. Lett.* 29, 126709. doi:10.1016/j.bml.2019.126709

Wang, M. X., Huo, L. M., Yang, H. C., Gao, Y. J., and E, Z. (1986). An Experimental Study on the Photodynamic Activity of Berberine *In Vitro* on Cancer Cells. *J. Tradit Chin. Med.* 6, 125–127.

Wang, Q., Gan, H., Chen, C., Sun, Y., Chen, J., Xu, M., et al. (2017). Identification and Validation of a 44-gene Expression Signature for the Classification of Renal Cell Carcinomas. *J. Exp. Clin. Cancer Res.* 36, 176. doi:10.1186/s13046-017-0651-9

Yu, F. S., Yang, J. S., Lin, H. J., Yu, C. S., Tan, T. W., Lin, Y. T., et al. (2007). Berberine Inhibits WEHI-3 Leukemia Cells *In Vivo*. *In Vivo* 21, 407–412. doi:10.1096/fasebj.21.5.a382-c

Zheng, F., Tang, Q., Wu, J., Zhao, S., Liang, Z., Li, L., et al. (2014). p38α MAPK-Mediated Induction and Interaction of FOXO3a and P53 Contribute to the Inhibited-Growth and Induced-Apoptosis of Human Lung Adenocarcinoma Cells by Berberine. *J. Exp. Clin. Cancer Res.* 33, 36. doi:10.1186/1756-9966-33-36

Zhou, Q., Erfati, R., Talvinen, K., Pospišil, H., Syväoja, J. E., and Collan, Y. (2008). Genomic Changes of the 55 kDa Subunit of DNA Polymerase Epsilon in Human Breast Cancer. *Cancer Genomics Proteomics* 5, 287–292.

Ziegler, Y., Laws, M. J., Sanabria Guillen, V., Kim, S. H., Dey, P., Smith, B. P., et al. (2019). Suppression of FOXM1 Activities and Breast Cancer Growth *In Vitro* and *In Vivo* by a New Class of Compounds. *NPJ Breast Cancer* 5, 45. doi:10.1038/s41523-019-0141-7

**Conflict of Interest:** The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

**Publisher’s Note:** All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Copyright © 2022 Ni, Sun, Fan, Li, Ren and Li. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.